Niemann-Pick Disease Type C
A rare, progressive neurodegenerative disorder caused by impaired intracellular cholesterol and lipid transport, most often due to mutations in the NPC1 gene.
- Caused by NPC1 or NPC2 gene mutations
- Impaired cellular cholesterol trafficking
- Autosomal recessive inheritance
- Disease-modifying therapy available
- Disease Group
- Lysosomal Storage Disorders
- Inheritance Pattern
- Autosomal Recessive (NPC1 95%, NPC2)
- Onset Range
- Infancy to Adulthood, highly variable
- Advanced Therapies
- Substrate Reduction Therapy, Research into CNS-targeted approaches
Condition Overview
Niemann-Pick Disease Type C (NPC) is a rare, progressive disorder caused by mutations in the NPC1 gene (about 95% of cases) or the NPC2 gene, which disrupt intracellular trafficking of cholesterol and other lipids. This leads to abnormal accumulation of cholesterol and sphingolipids within cells, particularly affecting the brain, liver, and spleen.
NPC is distinct from Niemann-Pick Disease Type A/B, despite the similar name; it involves a cholesterol transport defect rather than a sulfatase or sphingomyelinase enzyme deficiency. The age of onset and symptom pattern vary widely, from a severe early-infantile presentation with liver disease to adolescent or adult-onset forms presenting primarily with neurological and psychiatric symptoms.
Because early NPC symptoms can resemble other neurological or psychiatric conditions, diagnosis is often delayed. Recognizing characteristic clinical clues, such as vertical gaze palsy combined with ataxia and cognitive decline, supports earlier diagnosis and access to disease-modifying therapy.
Types and Clinical Subtypes
NPC is classified by age of neurological symptom onset, which strongly influences disease course.
Symptoms and Signs
Symptoms reflect progressive cholesterol and lipid accumulation in the brain and other organs, with a pattern that varies by age of onset.
Causes and Risk Factors
NPC is caused entirely by inherited genetic mutations affecting cellular cholesterol transport; it is not related to lifestyle or environmental exposures.
Diagnosis and Investigations
Diagnosis combines characteristic clinical features, biomarker testing, and genetic confirmation.
Disease Severity Stratification
NPC does not use a tumor-style staging system; clinicians classify disease by age of neurological onset, which correlates with overall severity and rate of progression.
Standard Treatment Options
Management combines disease-modifying therapy with supportive, multidisciplinary symptom management.
Advanced and Emerging Treatment Options
Beyond approved substrate reduction therapy, research continues into additional approaches that could further modify disease course.
Substrate Reduction Therapy
Miglustat
Approved in many countries to slow progression of neurological symptoms in NPC by reducing glycosphingolipid synthesis.
Investigational Therapy
Cyclodextrin-based approaches
Intrathecal or systemic cyclodextrin compounds have been studied for their potential to mobilize accumulated cholesterol, with ongoing research into efficacy and optimal use.
Gene Therapy
Investigational gene therapy approaches
Early-phase research is exploring gene-based strategies targeting NPC1 function.
Biomarkers and Molecular Testing
Biomarker and genetic testing support diagnosis and ongoing disease monitoring in NPC.
When a Second Opinion May Be Important
Because NPC can mimic other neurological and psychiatric conditions, specialist re-evaluation can be important at several points in the care journey.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Prognosis in NPC varies considerably and is strongly influenced by the age of neurological symptom onset, with earlier-onset disease generally following a more rapid course.
Supportive Care and Living with NPC
Multidisciplinary supportive care helps manage symptoms and maintain quality of life as NPC progresses.
How CancerFax Helps You Explore Treatment Options
CancerFax can help patients and families with Niemann-Pick Disease Type C obtain specialist medical report review, coordinate second opinions, and connect with centers experienced in substrate reduction therapy and comprehensive NPC care.
Get a free case reviewFrequently Asked Questions
Niemann-Pick Disease Type C is a rare, progressive disorder caused by mutations in the NPC1 or NPC2 genes that impair intracellular cholesterol transport, leading to abnormal lipid accumulation in the brain and other organs.
No. Although they share a similar name, NPC is caused by a cholesterol transport defect (NPC1/NPC2), while Type A/B is caused by acid sphingomyelinase deficiency (SMPD1). They are managed differently.
Early signs often include clumsiness or ataxia, difficulty with vertical eye movements, learning difficulties, and in younger-onset disease, liver enlargement.
Diagnosis typically involves plasma biomarker testing for oxysterols followed by confirmatory NPC1 or NPC2 genetic testing.
Yes, miglustat is approved in many regions to slow progression of neurological symptoms; supportive multidisciplinary care addresses other aspects of the disease.
Yes. NPC can present in adolescence or adulthood, sometimes initially with psychiatric symptoms, which can delay diagnosis.
Care typically involves medical geneticists, neurologists, psychiatrists, hepatologists, and rehabilitation specialists.
Yes, progressive cognitive decline is common, with the rate and severity varying based on age of onset.
Yes. Because NPC is autosomal recessive, genetic counseling helps families understand recurrence risk and testing options for future pregnancies.
Yes. CancerFax can help patients and families review medical reports, coordinate second opinions with specialists experienced in NPC, and connect with centers offering substrate reduction therapy and research programs, including cross-border coordination where needed.
Get Expert Guidance for Niemann-Pick Disease Type C
Connect with specialists experienced in NPC to review your medical reports and discuss treatment options.